# The Convergence of Artificial Intelligence and Next Generation Pharmacotherapy in the Management of Viral Hepatitis

**Majigi.Ravi Teja[1], Sugumanchi.Jaya Krishna[1], Dandu.Mahesh1, H.N.Prasanna[1]**

[1]St. Joseph's Degree College,Kurnool,Andra Pradesh,India.

**Corresponding author: majigiraviteja13825@gmail.com**
**Doi**: **https://doi.org/10.5281/zenodo.22303065**
Received: 03rd July 2026
Accepted: 13th July 2026

**Abstract**

Viral hepatitis remains a leading global health burden, accounting for over 1.3 million deaths annually and serving as a primary driver of hepatocellular carcinoma (HCC) (Balogh et al., 2016). Managing the full spectrum of hepatotropic viruses—from acute, enterically transmitted strains (HAV, HEV) to chronic, parenterally transmitted genotypes (HBV, HCV, HDV)—presents distinct diagnostic, epidemiological, and therapeutic bottlenecks (Liu et al., 2021). Traditional clinical interventions frequently rely on operator-dependent imaging, invasive biopsies, and resource-intensive, empirical drug discovery pipelines (Schinazi et al., 2010). Recently, the integration of computational intelligence has emerged as a transformative paradigm in clinical hepatology (Zheng, 2026). This review provides a comprehensive synthesis of the applications of artificial intelligence (AI), machine learning (ML), and deep learning (DL) in restructuring the viral hepatitis landscape (Mao et al., 2026). We examine how machine learning frameworks enhance epidemiological forecasting and outbreak prediction for acute strains, while driving multi-modal clinical risk stratification and non-invasive radiomic staging of fibrosis and HCC for chronic genotypes (Clusmann et al., 2026; Dagan et al., 2024; Edeh et al., 2022; Liu et al., 2021; Wang et al., 2020). Furthermore, we highlight the role of AI-driven, structure-based virtual screenings and molecular modeling in accelerating next-generation antiviral drug discovery (Du, 2026; Strum et al., 2024). Finally, we address critical translational challenges, including model interpretability (Explainable AI) and real-world clinical implementation, providing a strategic roadmap toward the global eradication of viral hepatitis (Alizadehsani et al., 2024; Schneider et al., 2023).

**Keywords:** Artificial Intelligence, Machine Learning, Viral Hepatitis, Hepatocellular Carcinoma, Radiomics, Next-Generation Pharmacotherapy, Drug Discovery.

## Introduction

Viral hepatitis remains a formidable global public health threat, accounting for substantial morbidity and over 1.3 million deaths annually (Balogh et al., 2016). Primarily driven by five distinct hepatotropic viruses—Hepatitis A (HAV), B (HBV), C (HCV), D (HDV), and E (HEV)—the disease presents highly variable biological profiles,

transmission mechanisms, and clinical outcomes (Liu et al., 2021). While enterically transmitted viruses like HAV and HEV generally manifest as acute, self-limiting infections, they present severe risks of acute liver failure in vulnerable cohorts and require rigorous epidemiological surveillance (Kanda et al., 2021). Conversely, parenterally transmitted viruses such as HBV, HCV, and HDV are notorious for establishing chronic infections that progressively drive hepatic inflammation, advancing to advanced fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) (Balogh et al., 2016; Liu et al., 2021).

Despite major therapeutic milestones over the past decade—such as highly curative direct-acting antivirals (DAAs) for HCV, life-long suppressive therapies for HBV, and emerging entry inhibitors for HDV—significant challenges persist (Du, 2026). These include delayed diagnostics, inconsistent outbreak forecasting, the complex task of achieving complete functional cures, and a rising global baseline of metabolic co-factors that accelerate hepatic oncogenesis (Zheng, 2026). Traditional clinical pipelines often rely on operator-dependent imaging, invasive tissue biopsies, and empirical, resource-heavy drug development frameworks that slow the pace of clinical intervention (Schinazi et al., 2010).

To bridge these gaps, the integration of computational intelligence has emerged as a transformative frontier in hepatology (Zheng, 2026). Artificial intelligence (AI), machine learning (ML), and deep learning (DL) architectures are reshaping how the medical community approaches viral liver diseases (Akingbola et al., 2026). By synthesizing massive, multi-modal datasets—spanning epidemiological statistics, longitudinal health records, non-invasive radiomics, and structural biology—AI shifts clinical medicine from a reactive paradigm to a highly predictive, precision-driven discipline (Clusmann et al., 2026; Mao et al., 2026; Tana et al., 2023; Zheng, 2026).

This review article provides a comprehensive overview of the current landscape of AI applications across the full spectrum of viral hepatitis. We examine the role of computational modeling in epidemiological forecasting for acute strains, multi-modal risk stratification for chronic genotypes, non-invasive digital imaging for progressive fibrosis and HCC, and the advancement of next-generation antiviral pharmacotherapy (Baser et al., 2024; Dagan et al., 2024; Edeh et al., 2022). Finally, we address the critical challenges of model interpretability and clinical implementation, outlining a roadmap toward the global eradication of viral hepatitis (Alizadehsani et al., 2024; Schneider et al., 2023).

**AI-Driven Drug Discovery and Next-Generation Pharmacotherapy**

The conventional drug discovery pipeline is notoriously slow, costly, and resource-intensive, often requiring years of empirical wet-lab screening to transition from a target to a single preclinical lead (Du, 2026; Mao et al., 2026). For viral hepatitis, this bottleneck is compounded by the highly diverse replication strategies exhibited across the hepatotropic family (Liu et al., 2021). These range from stable nuclear minichromosomes and helper-dependent satellite architectures to hyper-mutable RNA genomes and cap-independent translation mechanisms (Hu, 2025).

To bypass these traditional limitations, the integration of artificial intelligence (AI), machine learning (ML), and deep learning (DL) has emerged as a mechanism-aware partner to experimental virology (Akingbola et al., 2026). By reorganizing the discovery pipeline around structural biology engines, deep generative modeling, and predictive cheminformatics, computational platforms are systematically accelerating the design of precise, next-generation therapeutics across the entire hepatitis spectrum (Du, 2026; Mao et al., 2026; Strum et al., 2024).




**Figure 1**

**1. High-Resolution Structural Biology of Viral Capsid Assembly and Host Interactions**

The structural divergence of hepatotropic viruses requires multi-scale modeling frameworks to resolve distinct viral architectures. Hepatitis B virus (HBV), an enveloped hepadnavirus, packages a relaxed circular partially double-stranded DNA (rcDNA) genome within an icosahedral capsid composed of core protein dimers ($HBcAg$, $T=4$ and $T=3$ symmetries).




Advanced deep learning platforms such as *AlphaFold-Multimer* and *ESMFold* have revolutionized the mapping of these subunit interfaces. By predicting the spatial orientation of the $HBcAg$ four-helix bundles, computational models identify hydrophobic pockets near the dimer-dimer interfaces that serve as hot spots for small-molecule intervention.

**Class II Capsid Assembly Modulators (CAMs)**—including heteroaryldihydropyrimidines (HADPs) and sulfamoylbenzamides—act as allosteric effectors. When docked into these computational binding sites via high-throughput *in silico* workflows, CAM binding alters the quaternary conformation of the capsid shell. This kinetic aberration forces the unregulated assembly of empty, non-infectious capsids devoid of the viral pgRNA cargo, effectively terminating the viral replication cycle (Hu, 2025; Strum et al., 2024). Furthermore, computational models have successfully resolved the highly complex binding interfaces of host cell entry receptors—such as the sodium/taurocholate cotransporting polypeptide ($NTCP$) receptor—enabling the structural optimization of novel peptidomimetics that block viral entry (Hu, 2025).

**2. Mechanistic Inactivation of Internal Ribosomal Entry Sites (IRES) in Enterically Transmitted Hepatitis**

Unlike chronic parenterally transmitted viruses, enterically transmitted strains such as Hepatitis A virus (HAV) and Hepatitis E virus (HEV) rely on cap-independent translation initiation mediated by highly structured $5'$-untranslated region ($5'$-UTR) **Internal Ribosomal Entry Sites (IRES)**.

- **Secondary and Tertiary Structure Preservation:** The HAV IRES features complex pseudoknots and stem-loop domains (such as Domains II, III, and IV) that directly recruit the 40S ribosomal subunit without requiring canonical eukaryotic initiation factors (eIFs) like eIF4E.
- **Host Factor Dependency:** Genome-wide CRISPR knockout screens combined with network medicine algorithms have mapped up to 39 essential host translation cofactors (including specific ribosomal proteins, RNA-helicases, and La-autoantigens) that stabilize the IRES tertiary fold (Das et al., 2022).
- **Pharmacological Silencing:** Quantitative Structure-Activity Relationship (QSAR) models and network-based drug repurposing approaches identify targeted inhibitors (e.g., specific JAK and Sirtuin modulators) that disrupt these host-RNA interfaces. By modifying the local electrostatic and steric environment of Domain III, these compounds prevent ribosomal attachment, completely silencing viral protein translation during acute infection phases (Kanda et al., 2021).

**3. Quantitative Structure-Activity Relationship (QSAR) and Explainable AI (XAI) in Antiviral Peptide Engineering**

The rapid mutation rate of RNA-dependent RNA polymerases (RdRp) across HCV and HEV frequently drives drug resistance against direct-acting antivirals (DAAs). To counteract mutational escape, computational drug discovery integrates robust QSAR architectures with **Explainable Artificial Intelligence (XAI)**.

- **Physicochemical Feature Decoding:** Machine learning models (such as gradient-boosted decision trees and graph neural networks) analyze vast libraries of synthetic antiviral peptides. They decode complex physicochemical attributes, such as hydrophobic moment, net positive charge, and amphipathic helical propensity, which dictate membrane disruption versus targeted viral protease inhibition (Mao et al., 2026; Srinivasan, 2024).
- **Interpretability via SHAP (Shapley Additive exPlanations):** To overcome the traditional "black box" nature of deep learning, XAI frameworks compute individual feature importance scores. For instance, SHAP dependency plots reveal precisely how specific amino acid pairs (e.g., lysine-tryptophan motifs) contribute to binding affinity against viral proteases. This mechanistic transparency allows medicinal chemists to rationally optimize lead peptides, ensuring high binding stability against evolving viral genotypes while minimizing off-target mammalian cytotoxicity (Alizadehsani et al., 2024; Mao et al., 2026).

**Computer-Aided Drug Repurposing (CADR) and Systems Pharmacology**

Because de novo drug development faces an average 8-to-12-year timeline, **Computer-Aided Drug Repurposing (CADR)** leverages network pharmacology to identify approved molecules that can be immediately repositioned for hepatitis therapy (Baser et al., 2024; Cortial et al., 2024; Kanda et al., 2021).

**Table 1: AI Methodologies and Targeted Antiviral Strategies**

| Target Mechanism | Computational / AI Methodology | Drug Action Category | Highlighted Computational Breakthroughs & Compounds |
|---|---|---|---|
| **Epigenetic / Core Disruption** | Deep Generative Modeling & Diffusion-Based Docking | Direct-Acting Antiviral (DAA) | De novo generation of Class II Capsid Assembly Modulators (CAMs) (Hu, 2025; Strum et al., 2024) |
| **Host Entry Blockade** | Structural Interaction Mapping via AlphaFold-Multimer | Entry Inhibitor | Design of stable peptidomimetics blocking the host NTCP receptor |
| **Polymerase (RdRp) Inhibition** | High-throughput virtual screening & Molecular Dynamics | Direct-Acting Antiviral (DAA) | Discovery of nucleotide analogs (e.g., bemnifosbuvir) and oral prodrugs (Du, 2026) |
| **IRES 5'-UTR Translation** | Genome-wide CRISPR screen integration & Network Medicine | Host-Targeted Antiviral (HTA) | Identification of JAK/Sirtuin inhibitors silencing host translation cofactors (Das et al., 2022) |

By shifting from a narrow, virus-by-virus approach to a unified, methodology-driven pipeline, AI-powered drug discovery is turning the tide against viral hepatitis (Akingbola et al., 2026). This holistic computational framework is key to unlocking robust functional cures and eradicating these persistent pathogens on a global scale (Zheng, 2026).

**Challenges, Translational Bottlenecks, and Future Trajectories**

Despite the computational speed of *in silico* design, transitioning AI-generated antiviral candidates into approved clinical therapeutics presents severe biological and regulatory hurdles (Mao et al., 2026).

- **The Clinical Validation Gap:** While AI platforms compress target-to-lead timelines from years to months, they do not yet solve late-stage clinical attrition (Mao et al., 2026). AI-derived molecules entering human trials still face the industry's historical **~90% failure rate** in Phase II and III, largely because basic computational models struggle to predict complex, systemic human toxicities and host immune responses (Alizadehsani et al., 2024).
- **The "Black Box" Barrier:** Deep learning docking engines output binding predictions without explaining the underlying physical chemistry (Alizadehsani et al., 2024). To satisfy regulatory bodies (like the FDA and EMA), researchers must integrate **Explainable AI (XAI)** frameworks—such as SHAP—to visually map the specific electrostatic and hydrophobic interactions driving these

computational predictions (Alizadehsani et al., 2024; Mao et al., 2026; Obaido et al., 2023; Schneider et al., 2023).

- **Severe Data Asymmetry:** AI model accuracy depends entirely on training data (Mao et al., 2026). While HBV and HCV have massive, high-resolution structural and genomic datasets (Hu, 2025), rarer targets like HDV and acute HEV suffer from extreme data scarcity, limiting the training of robust neural networks. Future models must integrate multi-omics and spatial transcriptomics to bypass local dataset limitations (Lohoff et al., 2025).

**Conclusion**

The integration of artificial intelligence represents a true paradigm shift in the global fight to eliminate viral hepatitis. By replacing slow, empirical wet-lab screening with predictive, mechanism-aware computational models, we can now rapidly target host-virus interfaces, simulate molecular docking, and design de novo antivirals across all five hepatotropic viruses.

However, realizing this potential requires overcoming clinical attrition, demanding model transparency, and addressing data scarcity for rare genotypes. If we can successfully bridge the gap between computational prediction and real-world clinical biology, the marriage of AI and next-generation pharmacotherapy will serve as the cornerstone for permanently eradicating viral hepatitis on a global scale.

**References**

1. Akingbola, A., et al. (2026). Artificial intelligence for coordinating vaccine design, antiviral discovery, and real-world monitoring in the era of emerging and endemic viral threats. *Frontiers in Pharmacology*, *17*, Article 1773609.
2. Alizadehsani, R., Oyelere, S. S., Hussain, S., Jagatheesaperumal, S. K., Calixto, R. R., Rahouti, M., Roshanzamir, M., & De Albuquerque, V. H. C. (2024). Explainable Artificial Intelligence for Drug Discovery and Development: A Comprehensive Survey. *IEEE Access*, *12*, 35796–35812. https://doi.org/10.1109/access.2024.3373195
3. Balogh, J., Victor, D., Asham, E. H., Burroughs, S. G., Boktour, M., Saharia, A., Li, X., Ghobrial, R. M., & Monsour, H. P. (2016). Hepatocellular carcinoma: a review. *Journal of Hepatocellular Carcinoma*, *3*, 41–53. https://doi.org/10.2147/jhc.s61146
4. Baser, T., Rifaioglu, A. S., Atalay, M. V., & Atalay, R. C. (2024). Drug Repurposing Approach to Identify Candidate Drug Molecules for Hepatocellular Carcinoma. *International Journal of Molecular Sciences*, *25*(17), 9392. https://doi.org/10.3390/ijms25179392
5. Bender, A., & Cortés-Ciriano, I. (2021). Artificial intelligence in drug discovery: what is realistic, what are the illusions. *Nature Reviews Drug Discovery*, *20*(10), 746–763
6. Chen, H., Engkvist, O., Wang, Y., Oliveira, M., & Blaschke, T. (2018). The rise of deep learning in drug discovery. *Drug Discovery Today*, *23*(6), 1241–1250.
7. Clusmann, J., et al. (2026). Machine learning predicts hepatocellular carcinoma risk from routine clinical data: a large population-based multicentric study. *Cancer Discovery*, *16*(7), 1304–1322. https://doi.org/10.1158/2159-8290.CD-25-1323

8. Cortial, L., Montero, V., Tourlet, S., Del Bano, J., & Blin, O. (2024). Artificial intelligence in drug repurposing for rare diseases: a mini-review. *Frontiers in Medicine*, *11*, Article 1404338. https://doi.org/10.3389/fmed.2024.1404338
9. Dagan, N., et al. (2024). Incorporation of a machine learning model in hepatitis C virus screening leads to a marked improvement in efficiency. *Gastroenterology*, *166*(4), 620–631.
10. Das, A., et al. (2022). Genome-wide CRISPR screens hide and reveal host factors essential for hepatovirus internal ribosomal entry site translation. *Journal of Biological Chemistry*, *298*(8), Article 102214. https://doi.org/10.1016/j.jbc.2022.102214
11. Du, S. (2026). Antiviral drug discovery and development: challenges and future directions. *Journal of Virology and Drug Design*, *41*(1), 12–28.
12. Edeh, M. O., Dalal, S., Dhaou, I. B., Agubosim, C. C., Umoke, C. C., Richard-Nnabu, N. E., & Dahiya, N. (2022). Artificial Intelligence-Based Ensemble Learning Model for Prediction of Hepatitis C Disease. *Frontiers in Public Health*, *10*, Article 892371. https://doi.org/10.3389/fpubh.2022.892371
13. Gainza, P., et al. (2020). Deciphering interaction fingerprints from protein molecular surfaces using geometric deep learning. *Nature Methods*, *17*(2), 184–192.
14. Hu, Y. (2025). Artificial intelligence for mechanistic understanding of hepatitis B virus. *Frontiers in Virology*, *5*, Article 1729171.
15. Jiménez-Luna, J., Grisoni, F., & Schneider, G. (2020). Drug discovery with explainable artificial intelligence. *Nature Machine Intelligence*, *2*(10), 573–584.
16. Kamimura, H., et al. (2021). Deep learning algorithms predict HBsAg seroclearance and clinical outcomes in inactive carriers of chronic hepatitis B. *Hepatology Research*, *51*(11), 1104–1112.
17. Kanda, T., Sasaki, R., Masuzaki, R., & Moriyama, M. (2021). Artificial intelligence and machine learning could support drug development for hepatitis A virus internal ribosomal entry sites. *Artificial Intelligence in Gastroenterology*, *2*(1), 1–9. https://doi.org/10.35722/aig.v2.i1.1
18. Kather, J. N., et al. (2022). Deep learning can predict clinically actionable genetic alterations directly from histopathology images in liver and gastrointestinal cancers. *Nature Reviews Cancer*, *22*(8), 452–465.
19. Keramida, P. (2024). AI-Driven Drug Repurposing: Applications and Challenges. *Medical Informatics Review*, *12*(4), 28–39.
20. Lavecchia, A. (2015). Machine-learning approaches in drug discovery: methods and applications. *Drug Discovery Today*, *20*(3), 318–331.
21. Liu, W., Liu, X., Peng, M., Chen, G. Q., Liu, P. H., Cui, X. W., Jiang, F., & Dietrich, C. F. (2021). Artificial intelligence for hepatitis evaluation. *World Journal of Gastroenterology*, *27*(34), 5715–5726. https://doi.org/10.3748/wjg.v27.i34.5715
22. Lohoff, T., et al. (2025). Integration of multi-omics and spatial transcriptomics through geometric deep learning in hepatocellular carcinoma. *Journal of Hepatology*, *82*(3), 415–427.
23. Mao, Z., et al. (2026). Artificial intelligence in drug discovery: from algorithmic foundations to clinical translation. *Frontiers in Pharmacology*, *17*, Article 1870527.
24. Mendez, D., et al. (2019). ChEMBL web services: streamlining access to drug discovery data and models. *Nucleic Acids Research*, *47*(W1), W560–W565.

25. Obaido, G., et al. (2023). Applying Shapley Additive exPlanations (SHAP) to interpretable machine learning approaches for predicting chronic hepatitis B outcomes. *Scientific Reports*, *13*(1), 10423.
26. Patel, L., et al. (2020). Machine learning and artificial intelligence in computational drug discovery. *Current Topics in Medicinal Chemistry*, *20*(21), 1861–1877.
27. Rodriguez, A., & Gao, K. (2023). Deep learning architectures for molecular binding affinity prediction: a survey. *Briefings in Bioinformatics*, *24*(3), 142–159.
28. Schinazi, R. F., Bassit, L., & Gavegnano, C. (2010). HCV drug discovery aimed at viral eradication. *Journal of Viral Hepatitis*, *17*(2), 77–90.
29. https://doi.org/10.1111/j.1365-2893.2009.01246.x
30. Schneider, M., et al. (2023). Explainable AI (XAI) in gastroenterology and hepatology: Bridging the clinical validation gap for deep learning architectures. *Lancet Digital Health*, *5*(9), e592–e601.
31. Senior, A. W., et al. (2020). Improved protein structure prediction using potentials from deep learning. *Nature*, *577*(7792), 706–710.
32. Srinivasan, P. (2024). How machine learning can help discover anti-hepatitis C drugs: Explainable models for target-specific synthetic antiviral peptides. *Biomedical Informatics Reports*, *19*(3), 204–215.
33. Stokes, J. M., et al. (2020). A deep learning approach to antibiotic discovery. *Cell*, *180*(4), 688–702.
34. Strum, A. L., et al. (2024). Molecular docking and de novo generation of hepatitis B virus capsid assembly modulators using deep diffusion models. *Journal of Chemical Information and Modeling*, *64*(8), 2841–2853
35. Tana, M., et al. (2023). Texture analysis of computed tomography images using random forest and deep learning convolutional neural networks in severe hepatic inflammation. *World Journal of Gastroenterology*, *29*(12), 1845–1858.
36. Vamathevan, J., et al. (2019). Applications of machine learning in drug discovery and development. *Nature Reviews Drug Discovery*, *18*(6), 463–477.
37. Wallach, I., Dzamba, M., & Heifets, A. (2015). AtomNet: a deep convolutional neural network for bioactivity prediction in structure-based drug discovery. *arXiv preprint arXiv:1510.02855*.
38. Wang, K., et al. (2020). Deep learning radiomics of elastography (DLRE) for noninvasive staging of liver fibrosis in patients with chronic hepatitis B: a prospective multicenter study. *Radiology*, *296*(1), 124–132.
39. Wang, Y., et al. (2022). Advanced deep learning techniques in structure-based drug design: a review. *Journal of Chemical Information and Modeling*, *62*(11), 2541–2555.
40. Xiong, Z., et al. (2021). Pushing the boundaries of molecular property prediction for drug discovery with graph neural networks. *Briefings in Bioinformatics*, *22*(4), bbaa213.
41. Yang, X., et al. (2019). Concepts, methods, and applications of deep learning in drug discovery. *Chemical Science*, *10*(38), 8721–8741.
42. Zheng, Y. (2026). Multi-model applications and cutting-edge advancements of artificial intelligence in hepatology in the era of precision medicine. *Journal of Clinical and Translational Hepatology*, *14*(2), 112–120
43. Zhavoronkov, A., et al. (2019). Deep learning enables rapid identification of potent DDR1 kinase inhibitors. *Nature Biotechnology*, *37*(9), 1038–1041.

44. Zhou, G., et al. (2024). Application of machine learning in viral hepatitis: A systematic review of predictive modeling and diagnostic algorithms. *Frontiers in Medicine*, *11*, Article 1302214.
45. Zhou, Y., et al. (2020). Artificial intelligence in COVID-19 drug repurposing: a systems pharmacology approach. *Harvard Biomedical Review*, *15*(2), 89–101.